BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32343676)

  • 1. The landscape of RNA polymerase II-associated chromatin interactions in prostate cancer.
    Ramanand SG; Chen Y; Yuan J; Daescu K; Lambros MB; Houlahan KE; Carreira S; Yuan W; Baek G; Sharp A; Paschalis A; Kanchwala M; Gao Y; Aslam A; Safdar N; Zhan X; Raj GV; Xing C; Boutros PC; de Bono J; Zhang MQ; Mani RS
    J Clin Invest; 2020 Aug; 130(8):3987-4005. PubMed ID: 32343676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissecting transcription of the 8q24-MYC locus in prostate cancer recognizes the equilibration between androgen receptor direct and indirect dual-functions.
    Guo J; Wei Z; Jia T; Wang L; Nama N; Liang J; Liao X; Liu X; Gao Y; Liu X; Wang K; Fu B; Chen SS
    J Transl Med; 2023 Oct; 21(1):716. PubMed ID: 37828515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p68/DdX5 supports β-catenin & RNAP II during androgen receptor mediated transcription in prostate cancer.
    Clark EL; Hadjimichael C; Temperley R; Barnard A; Fuller-Pace FV; Robson CN
    PLoS One; 2013; 8(1):e54150. PubMed ID: 23349811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phytochemical 3,3'-diindolylmethane decreases expression of AR-controlled DNA damage repair genes through repressive chromatin modifications and is associated with DNA damage in prostate cancer cells.
    Palomera-Sanchez Z; Watson GW; Wong CP; Beaver LM; Williams DE; Dashwood RH; Ho E
    J Nutr Biochem; 2017 Sep; 47():113-119. PubMed ID: 28582660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An AR-ERG transcriptional signature defined by long-range chromatin interactomes in prostate cancer cells.
    Zhang Z; Chng KR; Lingadahalli S; Chen Z; Liu MH; Do HH; Cai S; Rinaldi N; Poh HM; Li G; Sung YY; Heng CL; Core LJ; Tan SK; Ruan X; Lis JT; Kellis M; Ruan Y; Sung WK; Cheung E
    Genome Res; 2019 Feb; 29(2):223-235. PubMed ID: 30606742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure.
    Urbanucci A; Marttila S; Jänne OA; Visakorpi T
    Prostate; 2012 Aug; 72(11):1223-32. PubMed ID: 22212979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor enhancer usage and the chromatin regulatory landscape in human prostate cancers.
    Stelloo S; Bergman AM; Zwart W
    Endocr Relat Cancer; 2019 May; 26(5):R267-R285. PubMed ID: 30865928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.
    Jia L; Shen HC; Wantroba M; Khalid O; Liang G; Wang Q; Gentzschein E; Pinski JK; Stanczyk FZ; Jones PA; Coetzee GA
    Mol Cell Biol; 2006 Oct; 26(19):7331-41. PubMed ID: 16980632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.
    Berglund AE; Rounbehler RJ; Gerke T; Awasthi S; Cheng CH; Takhar M; Davicioni E; Alshalalfa M; Erho N; Klein EA; Freedland SJ; Ross AE; Schaeffer EM; Trock BJ; Den RB; Cleveland JL; Park JY; Dhillon J; Yamoah K
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):292-302. PubMed ID: 30367117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus.
    Zhang X; Cowper-Sal lari R; Bailey SD; Moore JH; Lupien M
    Genome Res; 2012 Aug; 22(8):1437-46. PubMed ID: 22665440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA2 co-opts TGFβ1/SMAD4 oncogenic signaling and inherited variants at 6q22 to modulate prostate cancer progression.
    Yang X; Zhang Q; Li S; Devarajan R; Luo B; Tan Z; Wang Z; Giannareas N; Wenta T; Ma W; Li Y; Yang Y; Manninen A; Wu S; Wei GH
    J Exp Clin Cancer Res; 2023 Aug; 42(1):198. PubMed ID: 37550764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
    Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
    J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel Reporter Assays Identify Altered Regulatory Role of rs684232 in Leading to Prostate Cancer Predisposition.
    Ren N; Liu Q; Yan L; Huang Q
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element.
    Kregel S; Bagamasbad P; He S; LaPensee E; Raji Y; Brogley M; Chinnaiyan A; Cieslik M; Robins DM
    Nucleic Acids Res; 2020 May; 48(9):4741-4755. PubMed ID: 32198885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
    Krause WC; Shafi AA; Nakka M; Weigel NL
    Int J Biochem Cell Biol; 2014 Sep; 54():49-59. PubMed ID: 25008967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of novel androgen receptor target genes in prostate cancer.
    Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
    Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
    Li N; Chen M; Truong S; Yan C; Buttyan R
    Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene.
    Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
    PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer.
    Wu L; Zhao JC; Kim J; Jin HJ; Wang CY; Yu J
    Cancer Res; 2013 Oct; 73(19):6068-79. PubMed ID: 23913826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.